Re: [NMusers] ASCO and pharmacometrics

From: Pascal Girard <pascal.girard_at_merckgroup.com>
Date: Fri, 8 Apr 2016 07:22:13 +0000

Dear Dennis, Joga, Naoto-san and All

Dennis, I fully agree with your two comments .

Concerning my mail, I should have written: the abstract "corrected by clini=
cians challenging **up to** the last comma and p-value." Which means they d=
id much more than looking at commas, which by the end greatly improved the =
abstract. They valued the work, care about science, wanted to understand an=
d by the end improved the abstract to give it all chances.

I fully concur also with Joga and believe this is the path to follow.

Kind regards

Pascal
Envoy? de mon iPhone

Le 7 avr. 2016 ? 19:11, Dennis Fisher <fisher_at_plessthan.com<mailto:fisher_at_p=
lessthan.com>> a ?crit :

I agree with Phil. I have presented recently at two large endocrine meetin=
gs, one in the US, one in Europe. In both cases, I took complicated PK/PD =
models and kept it simple, emphasizing how the models could / would be used=
 in clinical development and clinical practice. The response at both meeti=
ngs was excellent - lots of people expressing interest in the models (and, =
interestingly, two of the competitors to the company for which I was consul=
ting tried to enlist my consulting help).

And, I disagree with Nick's comment yesterday. Perhaps oncology clinicians=
 are concerned about commas (I cannot speak to that issue) but I truly doub=
t Nick's claim that they don't care about science - the advances in oncolog=
y in recent years have been remarkable.


Dennis Fisher MD
P < (The "P Less Than" Company)
Phone: 1-866-PLessThan (1-866-753-7784)
Fax: 1-866-PLessThan (1-866-753-7784)
www.PLessThan.com<http://www.plessthan.com/>



On Apr 7, 2016, at 7:49 AM, Lowe, Phil <phil.lowe_at_novartis.com<mailto:phil.=
lowe_at_novartis.com>> wrote:

I would echo Pascal's point. Getting pharmacometric work into large clinica=
l conferences is not straightforward. It can be done (see link)http://erj.e=
rsjournals.com/content/46/suppl_59/PA5091.abstract but note where I was in =
the author list as the sole modeller. It helps to work closely with the cli=
nicians on the messaging. That said, it was fun at the meeting, explaining =
the data and model curves to clinicians with them asking how such knowledge=
 could impact their patients. An eye-opener. Keep trying Naoto!

All the best, Phil

Philip J Lowe PhD
Executive Director Pharmacometrics Scientist
Novartis Pharma AG, WSJ-027.6.25 or WSJ-386.12.48.46
4056 Basel, Switzerland
Phone: +41 61 324 4676
phil.lowe_at_novartis.com<mailto:phil.lowe_at_novartis.com>

From: owner-nmusers_at_globomaxnm.com<mailto:owner-nmusers_at_globomaxnm.com> [ma=
ilto:owner-nmusers_at_globomaxnm.com] On Behalf Of Pascal Girard
Sent: 06 April 2016 10:39
To: Naoto Hayashi; jgrevel_at_btconnect.com<mailto:jgrevel_at_btconnect.com>
Cc: nmusers
Subject: RE: [NMusers] ASCO and pharmacometrics

Dear Naoto,

In the past, Rene Bruno got one poster accepted with discussion at ASCO. He=
 is our "champion" !

I got one accepted on model for Exp-Tumor Size - OS at European Cancer Cong=
ress 2013 . But I can tell you that a medical writer rewrote it entirely an=
d it took 1 month to get it reviewed and corrected by clinicians challengin=
g every comma and p-value.

To give you an idea of the respective size of the meetings: ACOP N=500, P=
AGE N>600, ECC N> 10,000, ASCO N>20,000.

So the advice I would give, is just improve the quality and readability of =
our abstract and it will make it. By readability, I mean show it to an onco=
logist clinician. If he does not understand, rewrite it with the help of a =
medical writer ...

With best regards / Mit freundlichen Gr??en / Cordialement

Pascal




This message and any attachment are confidential and may be privileged or o=
therwise protected from disclosure. If you are not the intended recipient, =
you must not copy this message or attachment or disclose the contents to an=
y other person. If you have received this transmission in error, please not=
ify the sender immediately and delete the message and any attachment from y=
our system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do n=
ot accept liability for any omissions or errors in this message which may a=
rise as a result of E-Mail-transmission or for damages resulting from any u=
nauthorized changes of the content of this message and any attachment there=
to. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not guara=
ntee that this message is free of viruses and does not accept liability for=
 any damages caused by any virus transmitted therewith.



Click http://www.merckgroup.com/disclaimer to access the German, French, Sp=
anish and Portuguese versions of this disclaimer.

Received on Fri Apr 08 2016 - 03:22:13 EDT

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:49:53 EDT